GlaxoSmithKline Unit Viiv Gets FDA Approval for First Injectable Treatment for HIV Pre-Exposure Prevention
21 December 2021 - 9:14AM
Dow Jones News
By Mary de Wet
The U.S. Food and Drug Administration said Monday that it has
approved Apretude, a drug by GlaxoSmithKline unit Viiv to reduce
the risk of sexually acquired HIV.
Apretude is the first injectable pre-exposure prophylaxis for
the virus that causes AIDS, the agency said.
"This injection, given every two months, will be critical to
addressing the HIV epidemic in the U.S., including helping
high-risk individuals and certain groups where adherence to daily
medication has been a major challenge or not a realistic option,"
said Dr. Debra Birnkrant, director of the Division of Antivirals in
the FDA's Center for Drug Evaluation and Research.
At-risk adults and adolescents weighing at least 77 pounds can
use Apretude, the FDA said.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
December 20, 2021 16:59 ET (21:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
